Mr. Speaker, our government recognizes the importance of Canadians having access to safe effective treatment such as Cystagon for rare diseases. We are committed to improving the affordability, accessibility, and the appropriate use of medication, and have proposed amendments to the Patented Medicines Regulations in order to prevent excessive prices for patented drugs, including those for rare diseases.
Health Canada's special access program continues to consider requests for access to treatment for patients with cystinosis when marketing drugs are not medically suitable.